Industry News

The Public-Private Partnership for Rare Neurodegenerative Diseases will work to enhance understanding and develop treatments for rare neurodegenerative diseases.

Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing.

Regulatory officials are addressing challenges in ensuring that clinical data can be relied on in making regulatory decisions.

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

EMA has recommended approval of Enjaymo for the treatment of hemolytic anemia in adult patients with cold agglutinin disease.

The White House hopes to expand US modern biotech manufacturing and reduce reliance on foreign sources of bioindustrial materials.

Leistritz’s Twin Extrusion Workshop, hosted from Nov. 29 to Dec. 1 in Warren, NJ, will dovetail classroom training and twin screw demonstrations.

WHO has awarded prequalification to GSK’s Mosquirix, an approved malaria vaccine.

Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.

Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.

In partnership with the University of Pittsburgh, ElevateBio will open its next manufacturing center in the city.

SIRIO is enhancing its strategy for small and medium nutrition brands as Lonza’s Sara Lesina joins as GM in Europe.

Sanofi’s Xenpozyme (olipudase alfa-rpcp) is now the only approved treatment for acid sphingomyelinase deficiency.

Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.

Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

As winter approaches, the next generation of COVID-19 vaccines are being prepared and scheduled, ready for distribution across Europe and the world.

Lonza has introduced X-ray powder diffraction capability at its Monteggio, Switzerland site.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Emerson’s new gas analysis solutions center, located in Cumbernauld, Scotland, intends to help plants meet sustainability goals.

Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.

Novavax’s COVID-19 vaccine, Nuvaxovid, can now be given to adolescents aged 12 to 17 in the UK.

The European Union publishes long-awaited changes to Annex 1.

Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.

Watson-Marlow and Franz Ziel GmbH have launched a new integrated solution to fast-track cell, gene, and biological therapies.

ChargePoint Technology has acquired single-use container company PuroVaso.

Anthony Fauci announced that he plans to step down as Director of the National Institute of Allergy and Infectious Diseases in December 2022.